What Is Pharmaceutical Packaging material testing?
Pharmaceutical packaging material testing is the laboratory verification of materials and systems used to contain, protect, and deliver drug products — glass vials, ampoules, bottles; plastic bottles, films, and closures; rubber stoppers; aluminum foil and blister laminates; collapsible tubes; paper and paperboard — against the pharmacopoeial and regulatory standards that govern their safety, compatibility, and performance. The core framework combines USP ⟨660⟩ / ⟨661⟩ / ⟨671⟩ (US Pharmacopeia containers, materials, and performance), EP 3.2.1 / 3.1.x (European Pharmacopeia glass, plastics, rubber), JP (Japanese Pharmacopeia), the Chinese YBB series of national drug-packaging-material standards and the 2025 Chinese Pharmacopoeia 1+4+58 system, plus the underlying physical-test standards ISO, ASTM, and ISTA. A complete program confirms chemical inertness, mechanical integrity, barrier performance, and biological safety of the primary packaging in one coordinated test package.
Pharmaceutical packaging is not a passive container — it is a regulatory-defined component of the drug product, and a packaging failure is treated as a drug failure. Beijing ZKGX Research Institute structures its pharmaceutical packaging programs around the pharmacopoeial and YBB clause matrix, with each measurement traceable to the exact clause being verified.
Why Pharmaceutical Packaging Material Testing Matters
A primary pharmaceutical package is in continuous contact with the drug product for the entire shelf life. The failure modes the test program targets are well documented:
- Chemical leaching — extractables from glass (alkali ions), plastic (plasticizers, residual monomers), rubber (vulcanizers, accelerators), and coatings migrate into the drug, altering its potency or introducing toxic substances
- Sorption — the packaging adsorbs or absorbs the drug's active ingredients or excipients, reducing delivered dose
- Permeation — water vapor, oxygen, or light penetrates the package wall, degrading the drug through hydrolysis, oxidation, or photodegradation
- Mechanical failure — vial breakage, blister rupture, cap looseness, or seal failure during distribution
- Container-closure integrity (CCI) failure — microbial ingress through a defective seal contaminates a sterile product, the most safety-critical failure mode
- Biological reactivity — the packaging material itself causes cytotoxicity, irritation, or systemic toxicity in biological tests
For these reasons, packaging-material testing is mandatory in essentially every regulatory regime: US FDA requires compatibility data for new drug applications; the EU requires compliance with EP 3.x; China requires YBB registration and 2025 Pharmacopoeia compliance through the drug-packaging-material关联审评 (joint review with the drug application). Skipping the test means rejection of the drug application or, worse, a field failure that triggers recall and liability.
Which Standards Govern Pharmaceutical Packaging Material Testing?
There is no single global standard; the framework is layered across pharmacopoeial, regulatory, and physical-test standards:
| Standard | Scope | What it answers |
|---|---|---|
| USP ⟨660⟩ | Containers — Glass | Is this glass container Type I, II, or III by hydrolytic resistance? |
| USP ⟨661⟩ | Plastic packaging systems and their materials of construction | Does this plastic comply with physicochemical and biological tests? |
| USP ⟨671⟩ | Containers — Performance testing | What is the moisture vapor transmission rate and light transmission? |
| USP ⟨1660⟩ / ⟨1663⟩ / ⟨1664⟩ | Inner-surface durability, extractables, leachables | What substances migrate from the package, and how much? |
| EP 3.2.1 | Glass containers for pharmaceutical use | The European equivalent of USP ⟨660⟩ |
| EP 3.1.x series | Materials for containers — plastics, silicone, PVC, polyolefins, rubber | Material-level requirements for European compliance |
| JP 7.02 / 7.03 | Japanese Pharmacopeia container tests | Japan's analog to USP / EP |
| YBB 00032005-2015 onward (130 standards) | China national drug-packaging-material standards | Direct-contact drug packaging materials and containers — glass, plastic, rubber, metal, paper |
| YBB 00142002-2015 | China — Drug–packaging compatibility test guidance | How is compatibility testing designed and conducted? |
| 2025 Chinese Pharmacopoeia 1+4+58 | Restructured drug-packaging standards (1 general principle + 4 material categories + 58 product standards) | The new unified Chinese framework replacing "one product one standard" YBB approach |
| ISO 15378 | Primary packaging materials for medicinal products — GMP | Is the packaging manufactured under GMP for medicinal products? |
| ASTM D4169 / ISTA 3A | Performance testing of packaging systems for distribution | Can the package survive the distribution environment? |
| USP ⟨381⟩ / EP 3.2.9 | Elastomeric closures for parenterals | Do rubber stoppers meet fragmentation, self-sealability, and extractables limits? |
Beijing ZKGX structures every pharmaceutical-packaging test report against this matrix so the client can see which clause of which standard each measurement satisfies — not just a pass/fail verdict.
What Are the Core Test Items by Material Type?
The test program divides into five material-specific blocks plus a shared biological/performance layer.
1. Glass Containers (USP ⟨660⟩ / EP 3.2.1 / YBB 00342003)
Glass is the gold-standard pharmaceutical container because of its chemical inertness — but only Type I borosilicate delivers that inertness. Tests cover:
- Hydrolytic resistance (grain test at 121 °C per ISO 720 or surface test per USP ⟨660⟩) — Type I ≤ 1.0 mL of 0.02 N H₂SO₄ per 10 g of crushed glass; Type II and III have progressively higher limits
- Powdered glass test — crush the container, autoclave in water, titrate leached alkali; USP official method, more severe than the whole-container test
- Water attack test — for surface-treated soda-lime containers; less aggressive than powdered glass, suitable for Type II
- Arsenic test — for aqueous parenteral containers; absorbance of test solution must not exceed that of a 0.1 mL arsenic standard
- Thermal shock resistance — temperature differential between hot and cold water baths; small ampoules withstand 60–80 °C, 1-pint bottles 30–40 °C
- Internal bursting pressure — increment-pressure test to failure
For the relationship between borosilicate 3.3 and low-borosilicate Type I glass, see our Low-borosilicate glass testing program.
2. Plastic Containers (USP ⟨661⟩ / EP 3.1.x / 2025 Pharmacopoeia General Rule 9624)
Plastics — polyethylene, polypropylene, PVC, PET, polystyrene — are tested for their unique interaction risks:
- Light absorption of aqueous extract — absorbance 220–360 nm must be ≤ 2.0
- Non-volatile residue of extract — limit per USP class (Class I–VI) and material type
- Heavy metals in extract — typically ≤ 1 ppm as Pb
- Buffering capacity — titre difference vs blank must be within limit
- Oxidizable substances — permanganate consumption must be within limit
- Water vapor permeability — fill containers, seal, weigh, store 14 days at 60±5% RH / 20–25 °C; loss in weight ≤ 0.2%
- Collapsibility — squeeze containers must yield ≥ 90% of nominal contents at the required flow rate
- Biological reactivity per USP ⟨88⟩ Class VI — implantation, systemic injection, intracutaneous tests
3. Rubber Closures / Elastomeric Stoppers (USP ⟨381⟩ / EP 3.2.9 / YBB rubber series)
Rubber closures are the most vulnerable component of an injectable package. Key tests:
- Penetrability — force required for a hypodermic needle to pierce the closure must be below the stated limit
- Fragmentation test — pierce 12 closures, 4 punctures each, filter the contents; fragments ≤ 10 per closure (≤ 15 for butyl rubber)
- Self-sealability — pierce 10 times with new needles, immerse in 0.1% methylene blue under vacuum; no trace of colored solution inside
- pH of aqueous extract — titre limits for NaOH and HCl
- Light absorption of extract at 220–360 nm — ≤ 2.0
- Reducing substances — permanganate consumption limit
- Residue on evaporation — ≤ 4 mg per 50 mL
- Extractables — boil closure in water under reflux for 4 h; residue within limit
4. Metal Containers and Aluminum Foil (YBB metal series)
- Lacquer adhesion — acetone rub test, no lifting of lacquer
- Lacquer flexibility — fold and rub, no peeling
- Lacquer compatibility — fill with product, store 45 °C / 72 h, no discoloration or gas formation
- Pinhole detection — critical for thin aluminum foil; tested by light transmission or dye penetration
5. Paper, Paperboard, and Strips/Blisters
- Strip and blister seal integrity — vacuum-desiccator test: submerge packages in water under vacuum; if no water ingress, sealing is intact
- Compression strength of paperboard boxes
- Moisture content of paper components
- Print legibility and braille compliance for the EU market
Cross-Cutting Performance Tests (All Material Types)
Beyond the material-specific tests, four performance categories apply to nearly every pharmaceutical package:
Container-Closure Integrity (CCI)
The most safety-critical test for sterile products. Methods include:
- Vacuum decay (ASTM F2338) — most widely adopted deterministic method
- High-voltage leak detection (HVLD) — for liquid-filled products
- Helium leak detection — for highly sensitive applications
- Microbial ingress challenge — probabilistic method, immersion in challenge-bacteria suspension
- Dye ingress — vacuum/pressure cycle in methylene blue solution
Extractables and Leachables (E&L) Studies
The deepest interaction study between packaging and drug product:
- Extractables — exhaustive extraction in aggressive solvents to catalogue all possible migrants
- Leachables — measured migration into the actual drug formulation over shelf life, by GC-MS, LC-MS, ICP-MS
- AET (analytical evaluation threshold) — calculated per USP ⟨1663⟩ to determine which substances need toxicological review
Stability and Compatibility Studies
Per ICH Q1A (stability) and YBB 00142002-2015 (drug–packaging compatibility), the drug product is stored in the candidate package under long-term, intermediate, and accelerated conditions and re-tested at intervals. The package must not cause the drug to fall out of specification.
Distribution Simulation
Per ASTM D4169 or ISTA 3A, the packaged product is subjected to vibration, drop, compression, and climatic cycling that simulate global distribution. Distribution-simulation testing is required for new packaging systems and changes to existing ones.
Type vs. Production vs. Field Failure — Don't Confuse Them
Three regimes apply to pharmaceutical packaging over the product life cycle:
- Type approval / registration testing — done once per packaging system to support the drug application; the basis of legal sale. The full pharmacopoeial and E&L program lives here.
- Production conformity — periodic re-verification of production lots before release, typically the dimensional, CCI, and visual tests
- Field failure / OOS investigation — when a packaging-related complaint arrives, the same tests are run on retained samples and field returns to identify root cause
A common error is treating a production-conformity pass as evidence of pharmacopoeial type approval. It is not — the regimes have different purposes, different acceptance thresholds, and different regulatory weight. Beijing ZKGX labels every report with which regime the result serves.
How Long Does Pharmaceutical Packaging Material Testing Take?
The full pharmacopoeial type-approval program on a single primary package takes 6 to 12 weeks, dominated by:
- E&L studies — 8–10 weeks for extractables cataloguing and leachables method development
- Drug–packaging compatibility (ICH stability) — minimum 6 months for accelerated data, 12 months for intermediate, 36 months for long-term
- Hydrolytic resistance and chemical tests — typically 1–2 weeks
- CCI method development and validation — 4–8 weeks
Production-conformity runs much faster — 1 to 3 days per lot for the dimensional and CCI tests. Distribution simulation takes 2 to 4 weeks including conditioning.
Sample requirements: typically 30 to 50 production samples of the packaging component for the full pharmacopoeial program, plus 3 to 5 reference samples retained for re-testing. The drug product itself is needed for compatibility and E&L studies.
A formal test report is delivered within 5 to 7 working days after completion of each testing block, including raw data, chromatograms, photometric traces, dimensional measurements, and a clear statement of which clauses were met.
What Makes a Pharmaceutical Packaging Test Report Usable?
A report that only says "PASS" is useless when a regulatory reviewer or auditor challenges the package qualification. A defensible report — accepted by FDA, EMA, NMPA, PMDA, and ISO 15378 auditors — must contain:
- Material identification — actual measured composition (FTIR, density, melt-flow), not just "Type I glass"
- Measured values with units and tolerance — not "compliant," but "hydrolytic resistance 0.7 mL of 0.02 N H₂SO₄ per 10 g (Type I limit 1.0 mL, USP ⟨660⟩)"
- Standard-clause traceability — which paragraph of USP ⟨660⟩, EP 3.2.1, or YBB 00342003 each result is judged against
- Extractables and leachables catalogue — chromatographic identification of all detected substances, with concentration vs time
- Method validation data — recovery, linearity, LOD/LOQ for every analytical method
- Photo documentation — specimens before/after testing, any failure modes observed
- Signed conclusion — accredited laboratory stamp and ISO/IEC 17025 reference
Beijing ZKGX pharmaceutical-packaging reports follow this structure as standard and are issued under the laboratory's ISO/IEC 17025 accreditation framework, with each measurement traceable to a recognized national or international standard.
Frequently Asked Questions
Is pharmaceutical packaging material testing mandatory?
Yes, in every major market. Sale of a drug product in the US requires packaging data in the NDA/ANDA under USP standards; in the EU under EP standards and the Falsified Medicines Directive; in China under YBB / 2025 Pharmacopoeia through the joint-review mechanism. Imported drug products face the same requirements.
How is pharmaceutical packaging testing different from general packaging testing?
General express packaging material testing covers distribution safety of consumer-packaging materials — drop, compression, vibration — without the drug-contact and pharmacopoeial layer. Pharmaceutical packaging adds the chemical-interaction, biological-reactivity, container-closure-integrity, and stability layers that drug regulation requires. The two share some distribution methods but pharmaceutical packaging is a separate regulatory regime, not a subset.
What is the difference between extractables and leachables?
Extractables are substances that can be forced out of the package under aggressive conditions (high temperature, strong solvents) — a worst-case catalogue. Leachables are substances that actually migrate into the drug formulation under real storage conditions — the real-world exposure. Extractables inform what to look for; leachables tell you what is actually there. Both are needed because leachables without extractables is uninterpretable, and extractables without leachables is irrelevant.
Can the same package be used for a different drug product without re-testing?
No — not safely. The drug–packaging compatibility is product-specific: a vial cleared for one formulation may leach unacceptable substances into another with different pH, solvent system, or concentration. Each new drug–packaging combination requires its own compatibility and E&L study per YBB 00142002-2015 and ICH Q1A. The baby bottle testing program covers a similar "must retest for each new content" logic applied to food-contact bottles.
Does biologics packaging need different testing?
Stricter. Biologics (proteins, antibodies, vaccines) are particularly susceptible to adsorption by packaging surfaces, aggregation induced by leachables, and silicone-oil interactions with pre-filled syringes. The standard tests are the same, but the acceptance thresholds are tighter and additional tests (subvisible particle counting, protein adsorption, container–silicone interactions) are required.
References & Further Reading
- USP ⟨660⟩ — Containers — Glass (usp.org)
- USP ⟨661⟩ / ⟨671⟩ — Plastic packaging systems / Containers — Performance (usp.org)
- USP ⟨1663⟩ / ⟨1664⟩ — Assessment of extractables / Leachables (usp.org)
- EP 3.2.1 — Glass containers for pharmaceutical use (edqm.eu)
- EP 3.2.9 — Elastomeric closures for containers for aqueous parenteral preparations (edqm.eu)
- YBB series — China national drug-packaging-material standards (nifdc.org.cn)
- YBB 00142002-2015 — Drug–packaging compatibility test guidance (nifdc.org.cn)
- 2025 Chinese Pharmacopoeia 1+4+58 — Drug-packaging standards system (chp.gov.cn)
- ISO 15378 — Primary packaging materials for medicinal products — GMP (iso.org)
- ASTM D4169 — Standard practice for performance testing of shipping containers (astm.org)
- ASTM F2338 — Vacuum decay CCI test method (astm.org)
- ICH Q1A (R2) — Stability testing of new drug substances and products (ich.org)